Revelation Biosciences, Inc. (REVB) Stock Score, Valuation & Financial Research

Revelation Biosciences, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for REVB

Revelation Biosciences, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 0.72. These figures are a research snapshot, not a buy or sell recommendation.

What Revelation Biosciences, Inc. does

Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Revelation Biosciences is a clinical-stage life science company focused on the development of therapeutic candidates to rebalance inflammation and optimize patient health. The company does not currently generate revenue from product sales and relies on capital raises to fund its research and development activities.

Products and services

The company is developing Gemini, a proprietary formulation intended for the prevention of acute kidney injury (AKI) due to external stress such as surgical procedures or chemotherapy toxicity.

Brands and product families

Gemini — Proprietary formulation for rebalancing inflammation. Source

Customer types

Healthcare providers and hospitals.

Suppliers, materials and equipment

Contract Research Organizations (CROs) — The company relies on third-party contract research organizations to conduct its clinical trials and preclinical studies. Source
Contract Manufacturing Organizations (CMOs) — The company utilizes third-party contract manufacturing organizations for the production of its drug candidates. Source

Business strengths to evaluate

Proprietary Gemini formulation platform Source

Business risks and research considerations

History of operating losses and lack of revenue Source
Dependence on third-party clinical and manufacturing partners Source
Need for additional capital to fund operations Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

REVB financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:: Not currently available
Stored price:: USD 0.72
Market capitalization:: 2.87M (currency not supplied)
Revenue:: USD 0.00
Net income:: USD -10.75M
Free cash flow:: USD -8.27M
Cash:: USD 11.48M
Total debt:: USD 739.92K
EPS:: USD -7.00

What stands out

Free cash flow is USD -8.27M, negative for the stored period.
The balance sheet shows USD 11.48M of cash versus USD 739.92K of total debt, an excess of cash over debt on these two reported measures.
The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

Cash exceeds debt by USD 10.74M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for REVB

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

How long can REVB fund negative free cash flow using its current cash position before it may need more debt or new shares?
How is REVB likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
What specifically needs to improve for REVB to reach sustainable profitability?
What does the current fundamental change risk warning mean for the reliability or interpretation of REVB's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-15.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research REVB

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.